Saluggia, July 14, 2021 – DiaSorin S.p.A. (“DiaSorin”; FTSE MIB: DIA) announces it has completed the acquisition of Luminex Corporation (“Luminex”; NASDAQ: LMNX) for a price of USD 37.00 per share that corresponds to a total equity value of approximately USD 1.8 billion. Through the acquisition, DiaSorin will gain access to Luminex’s multiplexing technology and... Read more
– Provides Access To Proven Luminex Multiplexing Technology And Molecular Testing Solutions To Be Used In Unique Testing Panels, Generating Critical Mass In The Molecular Diagnostics Space – Sets The Ground For New Partnerships And Business Development Opportunities Through Life Science Offerings – Broadens DiaSorin’s Presence In The U.S. – Accelerates Luminex Technology And Solutions’... Read more
Luminex® Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. Luminex Submits Joint SARS-CoV-2 and Flu/RSV Respiratory Panel to FDA for Emergency Use Authorization Mar 10, 2021 6:30 AM EST AUSTIN, Texas, March 10, 2021 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an... Read more
Luminex® Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. Luminex Corporation to Participate at the 2021 Barclays Global Healthcare Conference Mar 09, 2021 11:35 AM EST AUSTIN, Texas, March 9, 2021 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, Chairman, CEO & President, and... Read more
Luminex® Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG® Respiratory Panel Test Including SARS-CoV-2 Mar 04, 2021 6:30 AM EST Provides labs with high throughput, syndromic respiratory testing capabilities AUSTIN, Texas, March 4, 2021... Read more
Luminex® Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. Luminex Receives BARDA Funding to Support Development and Validation of Test Combining SARS-CoV-2 and Flu/RSV Respiratory Panel Feb 19, 2021 6:30 AM EST ARIES® Assay will simultaneously detect influenza A/B, RSV, and SARS-CoV-2 in a single test,... Read more
Luminex® Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. Luminex Corporation Reports Fourth Quarter and Full-Year 2020 Results Feb 08, 2021 4:01 PM EST AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31,... Read more
Luminex® Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 8, 2021 AUSTIN, Texas, Jan. 27, 2021 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the fourth quarter ended December 31, 2020... Read more
Luminex® Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. Luminex Corporation Pre-Release of 4th Quarter 2020 Revenue Fourth Quarter Earnings Call Scheduled for February 8, 2021 AUSTIN, Texas, Jan. 12, 2021 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced 4th quarter 2020 revenue of approximately $111M, up... Read more
Luminex® Corporation (NASDAQ: LMNX) develops, manufactures, and markets proprietary biological testing technologies, with applications throughout the life-sciences industry. Luminex Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference AUSTIN, Texas, Dec. 16, 2020 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced that Nachum “Homi” Shamir, Chairman, CEO and President, and Harriss Currie, Senior Vice President and... Read more